152 results about "CD20" patented technology

The invention discloses a kit and method for detecting leukemia and lymphoma based on full-spectrum flow cytometry, the kit comprises 25 antibodies, the antibodies are specifically bound with fluorescein respectively, and leukemia and lymphoma are detected through full-spectrum flow cytometry; the 25 kinds of antibodies comprise HLA-DR (human leukocyte antigen-DR), CD38, CD7, CD34, Lambda, CD19, CD64, CD14, CD5, CD123, CD16, CD20, Kappa, CD117, CD13, CD45, CD11b, CD2, CD10, CD8, CD15, CD4, CD3, CD56 and CD33. The kit comprehensively covers development stages of various lines of bone marrow cells, and common abnormal expressions of various leukemia, myelodysplastic syndromes and lymphoma, and can preliminarily screen various leukemia and lymphoma.

The present invention provides dosing regimens of bispecific antibodies that target both CD3 and CD20 when used in the treatment of lymphoma, such as B cell non-Hodgkin lymphoma (B-NHL).

The present invention relates to the treatment of subjects having CD20-positive cell proliferative disorders (e.g., B cell proliferative disorders, such as non-Hodgkin's lymphomas). More specifically, the invention pertains to the treatment of subjects having a B cell proliferative disorder by subcutaneous administration of an anti-CD20 / anti-CD3 bispecific antibody.

The present invention relates to the treatment of subjects having CD20-positive cell proliferative disorders (e.g., B cell proliferative disorders, such as non-Hodgkin's lymphomas or chronic lymphocytic leukemia). More specifically, the invention pertains to the treatment of subjects having a B cell proliferative disorder by subcutaneous administration of mosunetuzumab as a monotherapy or in combination with lenalidomide.

The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.

The present disclosure provides bispecific chimeric antigen receptors targeting CD20 and BCMA. The CAR may comprise an scFv targeting CD20 and an scFv targeting BCMA, a hinge region, a transmembrane domain, a co-stimulatory region, and a cytoplasmic signaling domain. The chimeric antigen receptors can be used to treat autoimmune disorders or cancer.

The present disclosure provides CD19 / CD20-binding domains and chimeric antigen receptors (CARs) based on the same, as well as corresponding nucleic acid molecules, vectors, cells, compositions, methods and uses, e.g., for the prevention and / or treatment of cancer and / or autoimmune disease.

Provided is a chimeric antigen receptor (CAR) or a T cell receptor (TCR) comprising one or more of the antigen binding motifs disclosed herein. Aspects of the disclosure relate to a polynucleotide encoding a chimeric antigen receptor (CAR) or a T cell receptor (TCR) comprising one or more of the antigen binding motifs. Provided are antibodies and antigen binding systems that comprise a binding motif that binds CD20 and optionally a binding motif that binds CD19, and methods of producing and using the same. Antibodies and antigen binding systems of the present disclosure comprise CARs that comprise an anti-CD20 binding motif and an anti-CD19 binding motif. Provided are compositions, such as antibodies and CARs that are or comprise an anti-CD20 / anti-CD19 antigen binding system of the present disclosure, and cell therapies comprising the same, are useful, e.g., in the treatment of cancer.

The present application discloses a pharmaceutical combination comprising a bispecific anti-CD3 / CD20 polypeptide complex and a second therapeutic agent, and use thereof in the preparation of a drug for treating non-Hodgkin lymphoma.

Disclosed are anti-CD20 antibody formulations and uses of anti-CD20 antibodies for the treatment of CD20-positive diseases, including methods of using anti-CD20 antibodies to treat CD20-positive diseases, such as neuromyelitis optica spectrum disorder (NMOSD), non-Hodgkin's lymphoma (NHL), multiple sclerosis (MS), immune thrombocytopenia (ITP), rheumatoid arthritis (RA), Wegener's granulomatosis (WG), microscopic polyangiitis (MPA), lupus nephritis, systemic lupus erythematosus, and chronic lymphocytic leukemia (CLL).

The invention discloses a preparation method and application of an anti-human CD20 nano antibody and a bivalent nano antibody, and belongs to the technical field of nano antibodies. The anti-human CD20 nano antibody or the antigen binding fragment thereof provided by the invention comprises three complementary determining regions CDR1, CDR2 and CDR3, the amino acid sequence of the CDR1 is the 26th to 33rd sites of SEQ ID NO: 1, the amino acid sequence of the CDR2 is the 51st to 57th sites of SEQ ID NO: 1, and the amino acid sequence of the CDR3 is the 96th to 110th sites of SEQ ID NO: 1. Experiments show that the conjugates are coupled with gamma delta T cells to specifically kill CD20 positive tumor cells, the possibility of medicine formation is achieved, and a new direction is provided for treatment of CD20 target spots.

Antibodies are provided which comprise at least one Fab portion that binds CD47 and at least one Fab portion that binds the tumor associated antigen (TAA) CD20; wherein the Fab portion that binds CD47 exhibits low affinity for CD47; and, wherein the Fab portion that binds CD20 exhibits high affinity for CD20; and, wherein the antibody selectively binds CD47 and blocks CD47 interaction with SIRPα in tumor cells while exhibiting no substantial binding to CD47 in normal cells.

Disclosed herein, in on aspect, is a method of treating an immune or inflammatory disease, comprising administering to a subject in need thereof a therapeutically effective amount of an antibody or antigen-binding fragment thereof that binds to CD20 and CD3, thereby treating the immune or inflammatory disease.

Provided herein are methods of treating a subject having a CD20 - positive cell-proliferative disorder (e.g., a B-cell proliferative disorder, e.g., non-Hodgkin's lymphoma or chronic lymphocytic leukaemia).SOLUTION: The present invention provides the treatment of a subject having a B-cell proliferative disorder by subcutaneous administration of mosnetuzumab as monotherapy or in combination with lenalidomide.SELECTED DRAWING: Figure 10

This application provides a new NMT inhibitor and an antibody-drug conjugate (ADC) that comprises the NMT inhibitor as the payload tethered to an antibody, as well as a method for treating or preventing a disease or disorder associated with NMT, such as cancer associated with a cancerous cell that expresses HER2, CD19, CD20, or CD276 / 87-H3).

The present invention relates to the treatment of subjects having CD20-positive cell proliferative disorders (e.g., B cell proliferative disorders, such as non-Hodgkin's lymphomas or chronic lymphocytic leukemia). More specifically, the invention pertains to the treatment of subjects having a B cell proliferative disorder by subcutaneous administration of mosunetuzumab as a monotherapy or in combination with lenalidomide.

Aspects of the disclosure include methods of treating an autoimmune disease, including reducing the need for chronic immunosuppression, and for effectuating immune reset and / or producing a naive B cell repertoire in a subject in need thereof, the methods comprising administering a therapeutically effective amount of anti-CD20 yδ T cells to the subject, wherein the anti-CD20 yδ T cells express a chimeric antigen receptor (CAR) comprising a binding domain that specifically binds to CD20.

The present invention relates to the combined use of Fc [gamma] RIIb (CD32B) and CD20 specific antibodies, and specifically provides a method of treating a patient having a target cell expressing Fc [gamma] RIIb, the method comprising administering in combination (i) an antibody molecule that specifically binds to a surface antigen of the target cell, the antibody molecule having an Fc domain capable of binding Fc [gamma] RIIb; and (ii) an agent that inhibits or reduces binding between the Fc domain of the antibody molecule and Fc [gamma] RIIb, characterized in that the patient is selected on the basis of an increase in Fc [gamma] RIIb expression level of its target cell.

The application discloses a kind of bispecific anti-CD3 / CD20 antibodies and its application in B cell lymphoma, belong to the field of biological medicine technology.The bispecific antibody uses "tandem type" molecular structure, by the single-chain antibody (scFv) of anti-CD20 and the nanometer antibody (VHH) of anti-CD3 are fused by flexible connecting peptide.The high-purity bispecific antibody BsAb-20S3V is obtained by CHO cell stable expression system, and it has nanomolar level affinity to CD20+ and CD3+ cells.Experiments in vitro prove that the antibody can effectively mediate T cell specific killing to Raji cell, and the maximum killing rate can reach 75%-90%.In vivo pharmacodynamic evaluation shows that in tumor-bearing mouse model, high-dose group can significantly inhibit tumor growth and induce tumor negative growth.The antibody has good potential to prepare B cell lymphoma treatment drugs.

Provided is a use of a recombinant fusion protein in the preparation of a drug for treating an autoimmune disease that can benefit from the reduction or elimination of CD20+B cells (for example, CD20+ B cell depletion therapy). The recombinant fusion protein comprises i) a CD47-binding peptide, and ii) an anti-CD20 antibody or an antigen-binding portion thereof, wherein the CD47-binding peptide comprises a first extracellular Ig-like domain (SIRPαD1) of signal regulatory protein α (SIRPα), and the anti-CD20 antibody or the antigen-binding portion thereof comprises a heavy chain variable region, a heavy chain constant region, a light chain variable region, and a light chain constant region. The heavy chain variable region comprises VH-CDR1, VH-CDR2, and VH-CDR3, and the light chain variable region comprises VL-CDR1, VL-CDR2, and VL-CDR3, wherein the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 respectively comprise amino acid sequences as shown in GYTFTSYN (SEQ ID NO: 1), IYPGNGDT (SEQ ID NO: 2), ARSTYYGGDWYFNV (SEQ ID NO: 3), SSVSY (SEQ ID NO: 4), ATS, and QQWTSNPPT (SEQ ID NO: 5). The heavy chain constant region has the binding capacity for an FcR or a complement system protein. The CD47-binding peptide is linked to the N-terminus of the heavy chain variable region or light chain variable region of the anti-CD20 antibody or the antigen-binding portion thereof.

The present disclosure provides multiple anti-hCD20 mAbs as well as humanization of antibodies. The antibodies described herein are chicken-derived and exhibit significantly enhanced B-cell-specific antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) potency as well as improved depletion of B lymphoma cells in vivo relative to Rituximab.

The invention provides a method of treating a patient having target cells that express FcγRIIb, the method comprising administering (i) an antibody molecule that specifically binds a surface antigen of the target cell, which antibody molecule has an Fc domain capable of binding FcγRIIb; in combination with (ii) an agent that prevents or reduces binding between the Fc domain of the antibody molecule and FcγRIIb; characterized in that the patient is selected on the basis that their target cells express an elevated level of FcγRIIb.

The invention discloses an antigen expression vector, a combination of the antigen expression vector and an antibody and application of the combination in cancer treatment. The antigen expression vector comprises one or more DMP-antigen coding gene units; the DMP-antigen coding gene is composed of two functional elements DMP and an antigen coding gene, the DMP is an NF-kappa B specific promoter, and the antigen coding gene is an antigen molecule coding sequence. The antigen expression vector prepared by the invention can selectively express antigen molecules in cancer cells, an in-vivo delivery vector taking adeno-associated virus as the antigen expression vector, and a combination of an antigen CD20 expressed by the antigen expression vector and an anti-CD20 antibody rituximab. The compound has a good treatment effect on mouse colon cancer on mice and human colon cancer on humanized mice, and has good tumor targeting property and safety in the treatment of the cancer mice. The invention is expected to provide a new technology and a new reagent for the treatment of various cancer diseases.

The present invention relates to administration regimens for therapeutic proteins (e.g., bispecific antibodies that activate T cells) that mitigate cytokine release syndrome and infusion-related reactions. The methods employ an initial fractionated dosing with the optional administration of additional agents such as steroids or cytokine antagonists, which are discontinued at the maximum weekly dosage during the course of the dosing regimen.

The present invention relates to agents that inhibit the enzymatic activity of human CD39, for use in enhancing the activity of T-cell engager therapies in the treatment of disease, notably B cell Non-Hodgkin Lymphoma.

The invention relates to an application of an anti-CD20 antibody drug conjugate or a drug combination thereof in preparation of a drug for treating recurrent or refractory non-Hodgkin lymphoma after receiving at least one standard treatment schedule, and the drug combination comprises the anti-CD20 antibody drug conjugate and at least one therapeutic agent, the anti-CD20 antibody drug conjugate or the drug combination therapy containing the anti-CD20 antibody drug conjugate has a better curative effect compared with the existing clinical second-line standard therapy.

The present invention relates to a human CD20 protein of which one or more intracellular domains are modified sufficient to reduce or eliminate intracellular signaling when attached to or bound to a cell membrane, such as T cells, natural killer cells, B cells, myeloid cells, pluripotent stem cells, and hematopoietic stem cells. The invention also relates to a nucleic acid encoding the modified human CD20 protein described herein, and the use of the modified human CD20 protein as a safety switch in chimeric antigen receptor T cell therapy or as a selection marker in gene therapy.

To provide vials for single-dose administration of stable liquid pharmaceutical formulations comprising human CD20 and human bispecific antibodies that specifically bind to human CD3.SOLUTION: Provided is a single-dose vial comprising a human bispecific antibody that specifically binds to human CD20 and human CD3, a buffer comprising histidine at a concentration of 5 mM to 15 mM, polysorbate at a concentration of 0.05% to 0.15% w / v, sucrose at a concentration of 8% to 12% w / v, wherein the formulation has a pH of 5.8 ± 0.3.SELECTED DRAWING: None